Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Florida Health Daily.
April 2025
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | |
| 7 | 8 | 9 | 10 | 11 | 12 | 13 |
| 14 | 15 | 16 | 17 | 18 | 19 | 20 |
| 21 | 22 | 23 | 24 | 25 | 26 | 27 |
| 28 | 29 | 30 |
May 2025
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | |||
| 5 | 6 | 7 | 8 | 9 | 10 | 11 |
| 12 | 13 | 14 | 15 | 16 | 17 | 18 |
| 19 | 20 | 21 | 22 | 23 | 24 | 25 |
| 26 | 27 | 28 | 29 | 30 | 31 |
June 2025
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
| 1 | ||||||
| 2 | 3 | 4 | 5 | 6 | 7 | 8 |
| 9 | 10 | 11 | 12 | 13 | 14 | 15 |
| 16 | 17 | 18 | 19 | 20 | 21 | 22 |
| 23 | 24 | 25 | 26 | 27 | 28 | 29 |
| 30 |
Press releases published on March 27, 2025
Dr. Steve Siegal, MD Introduces Spatz Balloon Procedure in Fort Myers, Florida
EIN Presswire
·
March 27, 2025
Dr. Steve Siegal now offers the FDA-approved Spatz3 gastric balloon - an adjustable, non-surgical weight loss option with expert support and follow-up care. FORT MYERS, FL, UNITED STATES, March 27, 2025 /EINPresswire.com/ -- Dr. Steve Siegal is excited …
30% DROP IN FENTANYL OVERDOSE DEATHS A VICTORY
EIN Presswire
·
March 27, 2025
Signals More Need for Integrated Medical Care, Says FHE Health DEERFIELD BEACH, FL, UNITED STATES, March 27, 2025 /EINPresswire.com/ -- The national behavioral health provider, FHE Health, is calling for the expansion of integrated addiction care …
Entanglement Unleashes Prepaire™: A Game-Changing AI-Powered Biosurveillance Platform
EIN Presswire
·
March 27, 2025
Quantum-Inspired AI technology and data collection empowers public health leaders to predict emerging biological and other public health threats. MIAMI, FL, UNITED STATES, March 27, 2025 /EINPresswire.com/ -- Entanglement, Inc., a next-generation …
Entanglement, Inc. Unveils Revolutionary Products at eMerge Americas, Pioneering the Future of AI and Quantum Computing
EIN Presswire
·
March 27, 2025
Entanglement Inc. is a global powerhouse converging world leading scientists with creative technologists to lead the race in AI …
VitalHub Reports Fourth Quarter and Annual 2024 Results
GlobeNewswire
·
March 27, 2025
Annual Recurring Revenue (ARR)⁽¹⁻²⁾ up 59% YoY to $71.1 million Total Revenue up 51% YoY to $20.6 million Adjusted EBITDA ⁽²⁾ up 27% YoY to $5.0 million TORONTO, March 27, 2025 (GLOBE NEWSWIRE) -- Vitalhub Corp. (the “Company” or “VitalHub”) (TSX: VHI) ( …
Spectral AI Announces 2024 Fourth Quarter and Full Year Financial Results
GlobeNewswire
·
March 27, 2025
2024 Research …
Beta Bionics Announces Board Appointment of Gerard Michel
GlobeNewswire
·
March 27, 2025
IRVINE, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced the appointment of Gerard Michel as an independent member of its board …
Teva to Host Conference Call to Discuss First Quarter 2025 Financial Results at 8 a.m. ET on May 7, 2025
GlobeNewswire
·
March 27, 2025
TEL AVIV, Israel, March 27, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its first quarter 2025 financial results on Wednesday, May 7, 2025, at 7:00 a.m. ET. …
Teva Releases Q1 2025 Aide Memoire
GlobeNewswire
·
March 27, 2025
TEL AVIV, Israel, March 27, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q1 2025 Aide Memoire is available on the “Investors” page on its website. Q1 2025 Aide Memoire Teva has prepared this …
Annovis Bio, Inc. Receives Continued Listing Standard Notice From the NYSE
GlobeNewswire
·
March 27, 2025
MALVERN, Pa., March 27, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (AD) …
Tilray Brands, Inc. to Announce Third Quarter Fiscal 2025 Financial Results on April 8, 2025
GlobeNewswire
·
March 27, 2025
NEW YORK and LEAMINGTON, Ontario, March 27, 2025 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (“Tilray” or the “Company”) (Nasdaq: TLRY; TSX: TLRY), a global lifestyle and consumer packaged goods company at the forefront of beverage, cannabis and wellness …
Neuronetics Reports Updated Fourth Quarter and Full Year 2024 Financial and Operating Results
GlobeNewswire
·
March 27, 2025
MALVERN, Pa., March 27, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”) is issuing this press release to update the reporting of its financial results for the fourth quarter and full year ending December 31, 2024. …
Portage Biotech Reports Promising Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7
GlobeNewswire
·
March 27, 2025
DOVER, Del., March 27, 2025 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company with a portfolio of innovative therapeutics, presented new preclinical data for PORT-7 (TT-4), a selective Adenosine A2B receptor …
Precision Optics to Participate in the Lytham Partners 2025 Industrials & Basic Materials Investor Summit on April 1, 2025
GlobeNewswire
·
March 27, 2025
GARDNER, Mass., March 27, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ: POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, today announced that it will …
Nanobiotix Announces First Data From the Completed Dose Escalation Part of a Phase 1 Study Evaluating NBTXR3 (JNJ-1900) as a 2L+ Therapy for Patients With Locally Advanced NSCLC
GlobeNewswire
·
March 27, 2025
Data show favorable safety and confirm injection feasibility in 12 patients with locally advanced NSCLC amenable to re-irradiation for whom prior lines of therapy have failed A preliminary review of survival data showed 12-month LPFS of 64% (median 18.6 …
Nanobiotix annonce les premières données issues de la partie escalade de dose completée d’une étude de Phase 1 évaluant JNJ-1900 (NBTXR3) en traitement de 2L+ pour les patients atteints d’un CPNPC localement avancé
GlobeNewswire
·
March 27, 2025
Les données montrent un profil de sécurité favorable et confirment la faisabilité de l’injection chez 12 patients atteints d’un cancer du poumon (CPNPC) localement avancé éligibles à une ré-irradiation et pour lesquels les lignes de traitement antérieures …
Tempest Reports Year End 2024 Financial Results and Provides Business Update
GlobeNewswire
·
March 27, 2025
• Granted Both Orphan Drug …
INmune Bio Inc. Announces Year End 2024 Results and Provides a Business Update
GlobeNewswire
·
March 27, 2025
BOCA RATON, Fla., March 27, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, …
Lifecore Biomedical to Report Financial Results for Third Quarter of Fiscal 2025 on April 3, 2025
GlobeNewswire
·
March 27, 2025
CHASKA, Minn., March 27, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that it will report financial results for the third …
Elutia Announces GPO Agreement with Advantus Health Partners to Expand Access to EluPro™
GlobeNewswire
·
March 27, 2025
Seventh GPO Agreement Signed Since EluPro’s Launch SILVER SPRING, Md., March 27, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix products, announced that it has entered into an agreement …